NeuroOne Medical Technologies Corporation (Nasdaq: NMTC; “NeuroOne” or the “Company“), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today that it has executed an agreement with RBC Medical Innovations to develop and manufacture a proprietary radiofrequency (RF) generator for use with NeuroOne’s combination recording and ablation electrode that is being designed to both record brain activity and ablate brain tissue using the same electrode. Currently two separate hospital visits and surgeries are required to treat patients that have seizures due to epilepsy or brain tumors that contribute to seizures.
The combining of the diagnostic and therapeutic functions is expected to save time, money and potentially improve patient outcomes given the patient will be able to get both procedures performed with the same device and as part of the same procedure requiring one hospital visit. If successful, this will represent the Company’s first therapeutic product offering.
Dave Rosa, President and CEO of NeuroOne Medical Technologies Corporation says, “RBC is a well-respected firm with over 25 years of design, development and manufacturing of differentiated medical devices with some of the world’s largest and most innovative companies. We believe this partnership will allow NeuroOne to offer a proprietary complete system combining our game-changing combination ablation electrode with the hardware and software required to perform these procedures. This will allow us to fully participate in a market estimated in excess of $100M worldwide and growing. The project is expected to be completed in late 2022, pending receipt of regulatory clearance.”
Carl Mayer, President and CEO of RBC Medical Innovations says, “We are honored to partner with NeuroOne on this innovative new system that will significantly improve patient care. Using the cutting-edge Advantage Platforms™, RBC will reduce time-to-market, increase reliability and ultimately contribute to NeuroOne’s ongoing success.”
